Retatrutide / Cagrilintide Stack
A co-formulated metabolic research blend pairing retatrutide — an investigational triple GIP/GLP-1/glucagon receptor agonist — with cagrilintide, a long-acting amylin analog, in a single vial (12.5 mg / 2.5 mg). Studied for overlapping incretin and amylin signaling pathways. Both compounds are investigational and unapproved; provided strictly as a chemical reagent for laboratory research use only.
Studied Benefits
- Combines incretin (GLP-1/GIP/glucagon) and amylin research pathways in one vial
- Amylin-analog satiety signaling distinct from the GLP-1 axis
- Retatrutide 12.5 mg / Cagrilintide 2.5 mg co-formulation
- Investigational compounds — research use only, no approved combination exists
Research Use Only
This compound is intended for laboratory and research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional.
Independently Reviewed
We only list vendors that provide third-party, batch-specific COAs.
Affiliate disclosure: links above are affiliate partnerships. We may earn a commission at no cost to you.
Related in Stacks
Wolverine Stack (BPC-157 / TB-500)
The foundational blend research stack: Body Protection Compound-157 paired with Thymosin Beta-4 in a single vial, pairing localized tissue-repair research with systemic healing research. The base every other blend on this page builds on.
View product →
GLOW Stack (BPC-157 / TB-500 / GHK-Cu)
The Wolverine Stack plus GHK-Cu in one vial — extending tissue-repair research into collagen synthesis, gene-expression, and dermal/follicular pathways alongside the same BPC-157 and TB-500 foundation.
View product →
Make this protocol yours
The Engine reads your biometrics and personalizes dosing, timing, and stacking — free at engine.auraprotocols.com.
Try the Engine →